11 June 2020

Raphaël Duivenvoorden, theme Renal disorders, and colleagues, looked at the immune response of patients admitted to the hospital with a SARS-CoV-2 infection. They observed that monocytes, play an important role in the first line of defense against the coronavirus. Therefore, they investigated the effect of hydroxychloroquine on these cells. They have discovered an as yet unknown effect of hydroxychloroquine. It inhibits trained immunity, which is important in the first line of defense against infections. That is why they expect hydroxychloroquine to have no beneficial effect on the immune response in a SARS-CoV-2 infection.

They have published these findings in MedRxiv: Hydroxychloroquine inhibits trained immunity - implications for COVID-19 - Nils Rother, Cansu Yanginlar, Rik G.H. Lindeboom, Siroon Bekkering, Mandy M.T. van Leent, Baranca Buijsers, Inge Jonkman, Mark de Graaf, Marijke Baltissen, Lieke A. Lamers, Niels P. Riksen, Zahi A. Fayad, Willem J.M. Mulder, Luuk B. Hilbrands, Leo A.B. Joosten, Mihai G. Netea, Michiel Vermeulen, Johan van der Vlag, Raphaël Duivenvoorden. Articles in MedRxiv are not peer-reviewed.

Raphaël explained on the Dutch TV (NPO Op 1) about this research. You can wath this here
 

Related news items


Radboud Young Academy safeguards the future of science

21 January 2021

New platform to provide advice on policy, create an interdisciplinary network of early career scientists, and promote career development.

read more

Increase radio- and immunotherapy efficacy by targeting hypoxia

21 January 2021

In a paper recently accepted by Clinical Cancer Research, Daan Boreel, together with Paul Span, Sandra Heskamp, Gosse Adema and Jan Bussink, reviews the therapeutic potential of decreasing the lack of oxygen (hypoxia) often found in solid tumors.

read more

Radiation boost lowers risk of prostate cancer recurrence

21 January 2021

An additional external-beam radiation dose delivered directly to the tumor can benefit the prospects of men with non-metastatic prostate cancer, without causing additional side effects. The risk of relapse within five years for these men is smaller than for men who did not receive this boost.

read more

New research through grants for Radboudumc researchers

14 January 2021

Several researchers at the Radboudumc have received grants to start new studies, including on rare diseases, liver disease and cancer metastases. These are grants from the Dutch Research Council, European Joint Programme on Rare Diseases and the Gastric Liver Disease Foundation.

read more

Should we prepare for a corona-related depression wave? Indira Tendolkar and Eric Ruhé talk about their research projects

13 January 2021

Since the outbreak of the SARS-CoV-2, many of us have been staying at home in order to limit our social interactions, to keep ourselves and others safe from the virus. Yet, there’s also concern about what social distancing and anxiety generated by media reports are doing to people's mental health.

read more

RIMLS online award ceremony proudly presenting the winners

13 January 2021

In this special webinar of the RIMLS New Year Celebration, scientific director René Bindels reviewed 2020 and looked forward to 2021. But more importantly a number of researchers received prizes in the traditional RIMLS awards ceremony. 

read more